Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare skin emergency? tiny trial tests etanercept

NCT ID NCT02987257

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 38 times

Summary

This study tested whether the drug etanercept can help people with severe skin reactions called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Only 2 adults took part, receiving either etanercept or a placebo along with standard supportive care. The goal was to see how fast the skin healed and to collect samples for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEVENS-JOHNSON SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Emory University at Grady Memorial Hospital

    Atlanta, Georgia, 30303, United States

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland, 21224, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

  • University of California, Davis Medical Center

    Sacramento, California, 95817, United States

  • University of Florida Health Burn Center

    Gainesville, Florida, 32610, United States

  • University of Miami, Ryder Trauma Center

    Miami, Florida, 33136, United States

  • University of Tennessee Health Sciences Center

    Memphis, Tennessee, 38103, United States

  • University of Texas Medical Branch

    Galveston, Texas, 77555, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Washington, Harborview Medical Center

    Seattle, Washington, 98104, United States

  • Valleywise Health Medical Center

    Phoenix, Arizona, 85008, United States

  • Vanderblt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Wayne State University

    Detroit, Michigan, 48201, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

etanercept

What this could lead to

If it works, this could point toward a better treatment for severe skin reactions like Stevens-Johnson syndrome.

What could go wrong

This trial is very small (only 2 participants) and completed, so results may not apply to others. Etanercept may not speed healing or reduce risks.

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions Stevens-Johnson syndrome toxic epidermal necrolysis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.